Zomedica reported total revenue in the fourth quarter and full-year 2021 of $4.1 million. The company stated that its gross margin was 73.9%. It ended 2021 with cash and cash equivalents totaling $195 million.
Similarly, Will Zomedica recover?
ZOM stock will likely struggle to recover in price over the next few months. It’s going to be awhile before this early stage company will again have the chance to prove itself to investors. Having said that, investors with a high appetite for risk, and a willingness to go against the grain, may want to buy today.
What does Zomedica pharmaceuticals do? Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians.
Thereof, Why is Zomedica stock dropping?
The reason behind the decline goes back into the previous week, when Zomedica announced its third-quarter results after the market close on Nov. 12. The veterinary health company reported revenue in the third quarter of only $22,514. It posted a net loss of $6.3 million, or $0.091 per share.
What is happening to Zomedica?
Zomedica’s shares have plunged more than 80% after skyrocketing earlier this year. The company has experienced problems with a distribution partner being acquired and a development partner’s delays. Zomedica could rebound once new assays for its Truforma instrument are available.
Why did Zomedica stock drop?
The reason behind the decline goes back into the previous week, when Zomedica announced its third-quarter results after the market close on Nov. 12. The veterinary health company reported revenue in the third quarter of only $22,514. It posted a net loss of $6.3 million, or $0.091 per share.
Will TXMD stock go up?
Given the current short-term trend, the stock is expected to rise 26.62% during the next 3 months and, with a 90% probability hold a price between $0.33 and $0.58 at the end of this 3-month period.
Why is ZOM dropping?
CEO Robert Cohen said the move was precipitated by « changes at our current distributor that we believe have impacted its ability to market our products effectively. » Those words likely startled investors, many of whom decided to sell their shares. Zomedica’s stock price dropped sharply on Thursday.
Is Zomedica real?
Based in Ann Arbor, Michigan., Zomedica (NYSEAMERICAN:ZOM) specializes in veterinary testing and pharmaceutical products. ZOM stock is a risky bet in the pet diagnostics field, but it’s affordable and could provide powerful gains in the long-term.
When did Zom go public?
On April 18, 2019, the company became a public company via an initial public offering. After pricing at US$36 per share, the share price increased over 72% on the first day of trading. Prior to the IPO, Dropbox invested $5 million in Zoom.
How many employees are in Zomedica?
Zomedica Pharmaceuticals Inc. has 27 total employees across all of its locations and generates $4.13 million in sales (USD). There are 2 companies in the Zomedica Pharmaceuticals Inc. corporate family.
…
| Year | Operating Income |
|---|---|
| 2017 | -8.08 |
| 2018 | -16.58 |
| 2019 | -19.78 |
| 2020 | -16.76 |
Why is Zomedica tanking?
CEO Robert Cohen said the move was precipitated by « changes at our current distributor that we believe have impacted its ability to market our products effectively. » Those words likely startled investors, many of whom decided to sell their shares. Zomedica’s stock price dropped sharply on Thursday.
Is Zomedica a pump and dump?
Zomedica Pharmaceuticals (NYSEMKT:ZOM) stock is the latest pump-and-dump looking to take investors for a ride.
Will Zomedica stock go up tomorrow?
Tomorrow’s movement Prediction of Zomedica Pharmaceuticals Corp ZOM as on 08 Apr 2022 appears strongly Bullish . This stock started moving upwards as soon as it opened.
…
Munafa value: 55 as on 08 Fri Apr 2022.
| Upside target | 0.33 |
|---|---|
| Upside target | 0.31 |
| Downside target | 0.3 |
| Downside target | 0.29 |
Why is Zomedica rising?
Shares of Zomedica ( ZOM -0.69% ) climbed on Friday after the animal health specialist struck a deal to acquire Pulse Veterinary Technologies. By the close of trading today, Zomedica’s stock price was up 9.8% after rising as much as 21.2% earlier in the day.
What is truforma Zomedica?
Truforma is a blood testing kit for veterinarians. It’s based on bulk acoustic wave (BAW) sensors from Qorvo (NASDAQ:QRVO). The waves are run through pet blood samples to test for adrenal and thyroid diseases.
Did Zomedica reverse split?
Zomedica Says Reverse Stock Split Proposal Did Not Get Two-Thirds Majority Vote Required Under Canadian Law. Sept 25 (Reuters) – Zomedica Pharmaceuticals Corp <ZOM.
What is Truforma Zomedica?
Truforma is a blood testing kit for veterinarians. It’s based on bulk acoustic wave (BAW) sensors from Qorvo (NASDAQ:QRVO). The waves are run through pet blood samples to test for adrenal and thyroid diseases.
Is TXMD buy or sell?
A yield of 8.57% also means 8.57 cents of earnings for $1 of investment.
…
Momentum Scorecard. More Info.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.93% |
| 2 | Buy | 18.44% |
| 3 | Hold | 9.99% |
| 4 | Sell | 5.61% |
What is the future of Tilray stock?
The analysts following Tilray expect it to perhaps double its 2021 revenues in fiscal 2022. That means that it is possible for Tilray to reach $4 billion in 2024 if its trajectory continues as it has. In other words, it doubles in 2022 to reach $1 billion in revenue.
How high does IDEX go?
IDEX stock hit a 2022 high of $1.44 in early January and a low of $0.87 later in the same month. In 2021 its stock price ranged from 88 cents to $5.53. In an interview with Capital.com, Vinod Jain, senior analyst at Aite-Novarica Group, said “the stock could see more volatility due to its current price point”.
Join TheMoney.co community and don’t forget to share this post !
